Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Effects of autologous adipose-derived regenerative stem cells administered at the time of anterior cruciate ligament reconstruction on knee function and graft healing.

PMID: 31470759
Journal: Journal of Orthopaedic Surgery
Year: 2019
Reference: J Orthop Surg (Hong Kong). 2019 Sep-Dec;27(3):2309499019867580. doi: 10.1177/2309499019867580.
Impact factor:
Publication type: Paper in international publication
Authors: Alentorn-Geli, Eduard; Alvarez-Diaz, Pedro; Barastegui, David; Catala, Jordi; Cugat, Ramon; Cusco, Xavier; Garcia-Balletbo, Montserrat; Laiz, Patricia; Martinez-De la Torre, Adrian; Navarro, Jordi et al.
DOI: 10.1177/2309499019867580

Effects of long-term cysteamine treatment in patients with cystinosis.

PMID: 29260317
Journal: PEDIATRIC NEPHROLOGY
Year: 2019
Reference: Pediatr Nephrol. 2019 Apr;34(4):571-578. doi: 10.1007/s00467-017-3856-4. Epub 2017 Dec 19.
Impact factor: 2.816
Publication type: Review in national publication
Authors: Ariceta, Gema, Giordano, Vincenzo, Santos, Fernando et al.
DOI: 10.1007/s00467-017-3856-4

Effects of long-term cysteamine treatment in patients with cystinosis.

PMID: 29260317
Journal: PEDIATRIC NEPHROLOGY
Year: 2019
Reference: Pediatr Nephrol. 2019 Apr;34(4):571-578. doi: 10.1007/s00467-017-3856-4. Epub 2017 Dec 19.
Impact factor:
Publication type: Review in national publication
Authors: Ariceta, Gema; Giordano, Vincenzo; Santos, Fernando et al.
DOI: 10.1007/s00467-017-3856-4

Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy. Results of the EUROCONDOR Clinical Trial.

PMID: 30389750
Journal: DIABETES
Year: 2019
Reference: Diabetes. 2019 Feb;68(2):457-463. doi: 10.2337/db18-0682. Epub 2018 Nov 2.
Impact factor: 7.199
Publication type: Paper in international publication
Authors: Simo, Rafael, Hernandez, Cristina, Porta, Massimo, Bandello, Francesco, Grauslund, Jakob, Harding, Simon P, Aldington, Stephen J, Egan, Catherine, Frydkjaer-Olsen, Ulrik, Garcia-Arumi, Jose et al.
DOI: 10.2337/db18-0682

Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy. Results of the EUROCONDOR Clinical Trial.

PMID: 30389750
Journal: DIABETES
Year: 2019
Reference: Diabetes. 2019 Feb;68(2):457-463. doi: 10.2337/db18-0682. Epub 2018 Nov 2.
Impact factor:
Publication type: Paper in international publication
Authors: Aldington, Stephen J; Bandello, Francesco; Costa, Miguel Angelo; Cunha-Vaz, Jose; Egan, Catherine; Frydkjaer-Olsen, Ulrik; Garcia-Arumi, Jose; Gibson, Jonathan; Grauslund, Jakob; Harding, Simon P et al.
DOI: 10.2337/db18-0682

Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6.

PMID: 31108015
Journal: JOURNAL OF VIRAL HEPATITIS
Year: 2019
Reference: J Viral Hepat. 2019 Sep;26(9):1127-1138. doi: 10.1111/jvh.13132. Epub 2019 Jul 11.
Impact factor: 4.016
Publication type: Paper in international publication
Authors: Foster, Graham R, Rabinovitz, Mordechai, Burnevich, Eduard, Katchman, Helena, Tomasiewicz, Krzysztof, Lahser, Fred, Jackson, Beth, Shaughnessy, Melissa, Klopfer, Stephanie, Yeh, Wendy W et al.
DOI: 10.1111/jvh.13132

Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6.

PMID: 31108015
Journal: JOURNAL OF VIRAL HEPATITIS
Year: 2019
Reference: J Viral Hepat. 2019 Sep;26(9):1127-1138. doi: 10.1111/jvh.13132. Epub 2019 Jul 11.
Impact factor:
Publication type: Paper in international publication
Authors: Agarwal, Kaushik; Ari, Ziv Ben; Barr, Eliav; Bernhardi, David C; Borgia, Sergio; Brown, Ashley; Burnevich, Eduard; Burnevich, Eduard Z; Buti, Maria; Cohen, Michal et al.
DOI: 10.1111/jvh.13132

Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.

PMID: 31662866
Journal: United European Gastroenterology Journal
Year: 2019
Reference: United European Gastroenterol J. 2019 Oct;7(8):1093-1101. doi: 10.1177/2050640619862721. Epub 2019 Jul 3.
Impact factor: 3.453
Publication type: Paper in international publication
Authors: Trifan, Anca, Burta, Ovidiu, Tiuca, Nicoleta, Petrisor, Diana Corina, Lenghel, Augustin, Santos, Javier et al.
DOI: 10.1177/2050640619862721

Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.

PMID: 31662866
Journal: United European Gastroenterology Journal
Year: 2019
Reference: United European Gastroenterol J. 2019 Oct;7(8):1093-1101. doi: 10.1177/2050640619862721. Epub 2019 Jul 3.
Impact factor:
Publication type: Paper in international publication
Authors: Burta, Ovidiu; Lenghel, Augustin; Petrisor, Diana Corina; Santos, Javier; Tiuca, Nicoleta; Trifan, Anca et al.
DOI: 10.1177/2050640619862721

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

PMID: 30672091
Journal: JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
Year: 2019
Reference: J Peripher Nerv Syst. 2019 Mar;24(1):48-55. doi: 10.1111/jns.12302. Epub 2019 Feb 15.
Impact factor: 2.441
Publication type: Paper in international publication
Authors: Schmidt, J, Merkies, Ingemar S J, van Schaik, Ivo N, D'Amour, C, Kunc, P, Valis, M, Sussova, J, Kalous, T, Talab, R, Bednar, M et al.
DOI: 10.1111/jns.12302

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

PMID: 30672091
Journal: JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
Year: 2019
Reference: J Peripher Nerv Syst. 2019 Mar;24(1):48-55. doi: 10.1111/jns.12302. Epub 2019 Feb 15.
Impact factor:
Publication type: Paper in international publication
Authors: Ajroud-Driss, S; Akutsu, T; Algom, A; Allen, J; Antonia, M; Antonini, G; Attarian, S; Aufauvre, D; Auranen, M; Baba, M et al.
DOI: 10.1111/jns.12302

Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial.

PMID: 30739747
Journal: LANCET
Year: 2019
Reference: Lancet. 2019 Mar 9;393(10175):1021-1032. doi: 10.1016/S0140-6736(19)30195-3. Epub 2019 Feb 7.
Impact factor: 59.102
Publication type: Paper in international publication
Authors: Dodd, Robert, Ali, Hasan, Carhuapoma, J Ricardo, Kase, Carlos S, Lees, Kennedy R, Dawson, Jesse, Wilson, Alastair, Betz, Joshua F, Sugar, Elizabeth A, Hao, Yi et al.
DOI: 10.1016/S0140-6736(19)30195-3

Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial.

PMID: 30739747
Journal: LANCET
Year: 2019
Reference: Lancet. 2019 Mar 9;393(10175):1021-1032. doi: 10.1016/S0140-6736(19)30195-3. Epub 2019 Feb 7.
Impact factor:
Publication type: Paper in international publication
Authors: Abdul-Rahim, Azmil; Abou-Hamden, Amal; Abraham, Michael; Ahmed, Azam; Alba, Carlos Alarcon; Aldrich, E Francois; Ali, Hasan; Altschul, David; Amin-Hanjani, Sepideh; Anderson, Craig S et al.
DOI: 10.1016/S0140-6736(19)30195-3

Efficacy and safety of omalizumab (Xolair(R)) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial.

PMID: 30654196
Journal: Journal of Allergy and Clinical Immunology-In Practice
Year: 2019
Reference: J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1599-1609.e1. doi: 10.1016/j.jaip.2018.12.025. Epub 2019 Jan 15.
Impact factor: 7.55
Publication type: Paper in international publication
Authors: Nunez-Cordoba, Jorge M, Baeza, Maria Luisa, Echechipia, Susana, Gaig, Pere, Garcia, Blanca Esther, Labrador-Horrillo, Moises, Sala-Cunill, Ana, Bresco, Marina Sabate, Beristain, Ana, Quinones, Dolores et al.
DOI: 10.1016/j.jaip.2018.12.025

Efficacy and safety of omalizumab (Xolair(R)) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial.

PMID: 30654196
Journal: Journal of Allergy and Clinical Immunology-In Practice
Year: 2019
Reference: J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1599-1609.e1. doi: 10.1016/j.jaip.2018.12.025. Epub 2019 Jan 15.
Impact factor:
Publication type: Paper in international publication
Authors: Azofra, Julian; Baeza, Maria Luisa; Beristain, Ana; Bresco, Marina Sabate; Donado, Carmen Diaz; Echechipia, Susana; Ferrer, Marta; Gaig, Pere; Garcia, Blanca Esther; Gastaminza, Gabriel et al.
DOI: 10.1016/j.jaip.2018.12.025

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

PMID: 30043658
Journal: Multiple Sclerosis Journal
Year: 2019
Reference: Mult Scler. 2019 Aug;25(9):1255-1262. doi: 10.1177/1352458518789884. Epub 2018 Jul 25.
Impact factor: 5.649
Publication type: Paper in international publication
Authors: Cohen, Jeffrey A, Comi, Giancarlo, Arnold, Douglas L, Bar-Or, Amit, Selmaj, Krzysztof W, Steinman, Lawrence, Havrdova, Eva K, Cree, Bruce Ac, Montalban, Xavier, Hartung, Hans-Peter et al.
DOI: 10.1177/1352458518789884

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

PMID: 30043658
Journal: Multiple Sclerosis Journal
Year: 2019
Reference: Mult Scler. 2019 Aug;25(9):1255-1262. doi: 10.1177/1352458518789884. Epub 2018 Jul 25.
Impact factor:
Publication type: Paper in international publication
Authors: Arnold, Douglas L; Bar-Or, Amit; Cohen, Jeffrey A; Comi, Giancarlo; Cree, Bruce Ac; Frohna, Paul; Hartung, Hans-Peter; Havrdova, Eva K; Huang, Vivian; Kappos, Ludwig et al.
DOI: 10.1177/1352458518789884

Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial.

PMID: 31420397
Journal: BMJ Open
Year: 2019
Reference: BMJ Open. 2019 Aug 15;9(8):e030648. doi: 10.1136/bmjopen-2019-030648.
Impact factor: 2.376
Publication type: Paper in international publication
Authors: Vaquero, Jose Manuel, Paez-Vega, Aurora, Cantisan, Sara, Lobo-Acosta, Maria Angeles, Perez, Ana Belen, Alonso-Moralejo, Rodrigo, Iturbe, David, Monforte, Victor, Otero-Gonzalez, Isabel, Pastor, Amparo et al.
DOI: 10.1136/bmjopen-2019-030648

Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial.

PMID: 31420397
Journal: BMJ Open
Year: 2019
Reference: BMJ Open. 2019 Aug 15;9(8):e030648. doi: 10.1136/bmjopen-2019-030648.
Impact factor:
Publication type: Paper in international publication
Authors: Alonso-Moralejo, Rodrigo; Cantisan, Sara; Iturbe, David; Lobo-Acosta, Maria Angeles; Luque-Pineda, Antonio; Monforte, Victor; Otero-Gonzalez, Isabel; Paez-Vega, Aurora; Pastor, Amparo; Perez, Ana Belen et al.
DOI: 10.1136/bmjopen-2019-030648

Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).

PMID: 31433997
Journal: PULMONARY PHARMACOLOGY & THERAPEUTICS
Year: 2019
Reference: Pulm Pharmacol Ther. 2019 Oct;58:101834. doi: 10.1016/j.pupt.2019.101834. Epub 2019 Aug 18.
Impact factor: 2.669
Publication type: Paper in international publication
Authors: Loebinger, Michael R, Polverino, Eva, Blasi, Francesco, Elborn, Stuart J, Chalmers, James D, Tiddens, Harm Awm, Goossens, Herman, Tunney, Michael, Zhou, Wenchun, Angyalosi, Gerhild et al.
DOI: 10.1016/j.pupt.2019.101834

Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).

PMID: 31433997
Journal: PULMONARY PHARMACOLOGY & THERAPEUTICS
Year: 2019
Reference: Pulm Pharmacol Ther. 2019 Oct;58:101834. doi: 10.1016/j.pupt.2019.101834. Epub 2019 Aug 18.
Impact factor:
Publication type: Paper in international publication
Authors: Angyalosi, Gerhild; Blasi, Francesco; Chalmers, James D; Elborn, Stuart J; Goossens, Herman; Haworth, Charles S; Hill, Adam T; Loebinger, Michael R; Polverino, Eva; Tiddens, Harm Awm et al.
DOI: 10.1016/j.pupt.2019.101834

Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis.

PMID: 31162772
Journal: HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Year: 2019
Reference: Head Neck. 2019 Aug;41(8):2823-2829. doi: 10.1002/hed.25832. Epub 2019 Jun 4.
Impact factor: 2.442
Publication type: Review in international publication
Authors: Vuong, Huy Gia, Ho, An Thi Nhat, Tran, Thao T K, Capdevila, Jaume, Benekli, Mustafa, Nakazawa, Tadao, Katoh, Ryohei, Kondo, Tetsuo et al.
DOI: 10.1002/hed.25832

Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis.

PMID: 31162772
Journal: HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Year: 2019
Reference: Head Neck. 2019 Aug;41(8):2823-2829. doi: 10.1002/hed.25832. Epub 2019 Jun 4.
Impact factor:
Publication type: Review in international publication
Authors: Benekli, Mustafa; Capdevila, Jaume; Ho, An Thi Nhat; Katoh, Ryohei; Kondo, Tetsuo; Nakazawa, Tadao; Tran, Thao T K; Vuong, Huy Gia et al.
DOI: 10.1002/hed.25832

Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.

PMID: 30558818
Journal: VACCINE
Year: 2019
Reference: Vaccine. 2019 Mar 22;37(13):1876-1884. doi: 10.1016/j.vaccine.2018.11.074. Epub 2018 Dec 14.
Impact factor: 3.269
Publication type: Paper in international publication
Authors: Borja-Tabora, Charissa Fay Corazon, Montellano, May, Bravo, Lulu, Santos, Jaime, de Castro, Jo-Anne, Rivera-Medina, Doris Maribel, Cutland, Clare, Ariza, Miguel, Diez-Domingo, Javier, Gonzalez, Celia Diaz et al.
DOI: 10.1016/j.vaccine.2018.11.074

Publications

Publications searcher

Effects of autologous adipose-derived regenerative stem cells administered at the time of anterior cruciate ligament reconstruction on knee function and graft healing.

Effects of long-term cysteamine treatment in patients with cystinosis.

Effects of long-term cysteamine treatment in patients with cystinosis.

Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy. Results of the EUROCONDOR Clinical Trial.

Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy. Results of the EUROCONDOR Clinical Trial.

Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6.

Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6.

Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.

Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial.

Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial.

Efficacy and safety of omalizumab (Xolair(R)) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial.

Efficacy and safety of omalizumab (Xolair(R)) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial.

Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial.

Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).

Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).

Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis.

Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis.

Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.

Patronage:

Collaborating:

Accreditations: